Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 266

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape

Open access
Lim, Seung-Oe, Li, Chia-Wei, Xia, Weiya, Lee, Heng-Huan, Chang, Shih-Shin, Shen, Jia, Hsu, Jennifer L., Raftery, Daniel, Djukovic, Danijel, Gu, Haiwei, Chang, Wei-Chao, Wang, Hung-Ling, Chen, Mong-Liang, Huo, Longfei, Chen, Chung-Hsuan, Wu, Yun, Sahin, Aysegul, Hanash, Samir M., Hortobagyi, Gabriel N., Hung, Mien-Chie·2016·Cancer Research

Abstract

Oncogenic signaling reprograms cancer cell metabolism to augment the production of glycolytic metabolites in favor of tumor growth. The ability of cancer cells to evade immunosurveillance and the role of metabolic regulators in T-cell functions suggest that oncogene-induced metabolic reprogramming may be linked to immune escape. EGF signaling, frequently dysregulated in triple-negative breast cancer (TNBC), is also associated with increased glycolysis. Here, we demonstrated in TNBC cells that EGF signaling activates the first step in glycolysis, but impedes the last step, leading to an accumulation of metabolic intermediates in this pathway. Furthermore, we showed that one of these intermediates, fructose 1,6 bisphosphate (F1,6BP), directly binds to and enhances the activity of the EGFR, thereby increasing lactate excretion, which leads to inhibition of local cytotoxic T-cell activity. Notably, combining the glycolysis inhibitor 2-deoxy-d-glucose with the EGFR inhibitor gefitinib effectively suppressed TNBC cell proliferation and tumor growth. Our results illustrate how jointly targeting the EGFR/F1,6BP signaling axis may offer an immediately applicable therapeutic strategy to treat TNBC. Cancer Res; 76(5); 1284–96. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2478

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 266

Metadata

Authors
Lim, S.-O., Li, C.-W., Xia, W., Lee, H.-H., Chang, S.-S., Shen, J., Hsu, J. L., Raftery, D., Djukovic, D., Gu, H., Chang, W.-C., Wang, H.-L., Chen, M.-L., Huo, L., Chen, C.-H., Wu, Y., Sahin, A., Hanash, S. M., Hortobagyi, G. N., & Hung, M.-C.
Venue
Cancer Research
Published
2016-02-29
Volume
76
Issue
5
Pages
1284-1296
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2232897590
Cited by
266
References
47
FWCI
8.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2478
The paper
Lim, S.-O., Li, C.-W., Xia, W., Lee, H.-H., Chang, S.-S., Shen, J., Hsu, J. L., Raftery, D., Djukovic, D., Gu, H., Chang, W.-C., Wang, H.-L., Chen, M.-L., Huo, L., Chen, C.-H., Wu, Y., Sahin, A., Hanash, S. M., Hortobagyi, G. N., & Hung, M.-C. (2016). EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2478

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.